Posted by Michael Wonder on 23 Jul 2018
Allergan receives FDA fast track designation for AGN-241751 for the treatment of major depressive disorder
23 July 2018 - Phase 2 clinical study underway.
Allergan today announced the U.S. FDA has granted Fast Track designation for AGN-241751, an investigational new treatment for major depressive disorder.
AGN-241751 is a novel, oral, rapid-acting anti-depressant that recently entered Phase 2 development.
